{"id":21909,"date":"2023-02-21T21:30:00","date_gmt":"2023-02-21T13:30:00","guid":{"rendered":"https:\/\/flcube.com\/?p=21909"},"modified":"2025-01-18T21:34:08","modified_gmt":"2025-01-18T13:34:08","slug":"biocytogens-nano-100-project-aims-to-develop-over-100-fully-human-nanobody-drugs","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=21909","title":{"rendered":"Biocytogen&#8217;s &#8216;Nano 100 Project&#8217; Aims to Develop Over 100 Fully Human Nanobody Drugs"},"content":{"rendered":"\n<p>China-based Biocytogen Pharmaceuticals (Beijing) Co., Ltd has announced the launch of the \u201cNano 100 Project,\u201d an ambitious initiative designed to develop fully human nanobody drugs for over 100 targets. This project leverages Biocytogen\u2019s proprietary fully human nanobody mouse, RenNano, in conjunction with its high-throughput in vitro and in vivo antibody screening platforms, enabling large-scale development of fully human nanobody drugs.<\/p>\n\n\n\n<p><strong>RenNano Mouse and Its Capabilities<\/strong><br>Biocytogen successfully engineered the RenNano mouse from its fully human antibody mouse, RenMab. The RenNano mouse features full human heavy chain variable regions and is capable of producing heavy-chain-only antibodies (HCAbs). The variable regions of HCAbs, known as nanobodies, do not require in vitro humanization for drug development. Research has demonstrated that the RenNano mouse can generate robust immune responses following immunizations with various antigens. HCAbs produced by the RenNano mouse exhibit highly diverse CDR3 sequences and can recognize numerous epitopes with nM-level high affinities. In vitro and in vivo experiments have confirmed that antibodies derived from the RenNano mouse possess favorable biological functions.<\/p>\n\n\n\n<p><strong>Nano 100 Project Objectives and Collaborations<\/strong><br>Building on RenNano\u2019s exceptional ability to discover fully human nanobodies, Biocytogen has initiated the \u201cNano 100 Project.\u201d The project targets the development of fully human therapeutic nanobodies against over 100 targets, encompassing tumor-associated antigens (TAAs), GPCRs, immune checkpoints, cytokines, and factors related to neurological diseases. Biocytogen is actively seeking collaborations with global pharmaceutical and biotech companies. By combining its large-scale nanobody development capabilities with collaborators\u2019 expertise in nanobody-related therapeutics\u2014such as cell therapies, bispecific and multi-specific antibodies, ADCs, and RACs\u2014Biocytogen aims to develop novel drugs with first-in-class and\/or best-in-class potentials.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>China-based Biocytogen Pharmaceuticals (Beijing) Co., Ltd has announced the launch of the \u201cNano 100 Project,\u201d&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":false,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,6],"tags":[1519,30,28],"class_list":["post-21909","post","type-post","status-publish","format-standard","hentry","category-company","category-rd","tag-biocytogen-pharmaceuticals","tag-biotech","tag-multi-specific-antibodies"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Biocytogen&#039;s &#039;Nano 100 Project&#039; Aims to Develop Over 100 Fully Human Nanobody Drugs - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"China-based Biocytogen Pharmaceuticals (Beijing) Co., Ltd has announced the launch of the \u201cNano 100 Project,\u201d an ambitious initiative designed to develop fully human nanobody drugs for over 100 targets. This project leverages Biocytogen\u2019s proprietary fully human nanobody mouse, RenNano, in conjunction with its high-throughput in vitro and in vivo antibody screening platforms, enabling large-scale development of fully human nanobody drugs.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=21909\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Biocytogen&#039;s &#039;Nano 100 Project&#039; Aims to Develop Over 100 Fully Human Nanobody Drugs\" \/>\n<meta property=\"og:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=21909\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2023-02-21T13:30:00+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-01-18T13:34:08+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=21909#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=21909\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Biocytogen&#8217;s &#8216;Nano 100 Project&#8217; Aims to Develop Over 100 Fully Human Nanobody Drugs\",\"datePublished\":\"2023-02-21T13:30:00+00:00\",\"dateModified\":\"2025-01-18T13:34:08+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=21909\"},\"wordCount\":280,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"Biocytogen Pharmaceuticals\",\"Biotech\",\"Multi-specific antibodies\"],\"articleSection\":[\"Company\",\"R&amp;D\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=21909#respond\"]}],\"copyrightYear\":\"2023\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=21909\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=21909\",\"name\":\"Biocytogen's 'Nano 100 Project' Aims to Develop Over 100 Fully Human Nanobody Drugs - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2023-02-21T13:30:00+00:00\",\"dateModified\":\"2025-01-18T13:34:08+00:00\",\"description\":\"China-based Biocytogen Pharmaceuticals (Beijing) Co., Ltd has announced the launch of the \u201cNano 100 Project,\u201d an ambitious initiative designed to develop fully human nanobody drugs for over 100 targets. This project leverages Biocytogen\u2019s proprietary fully human nanobody mouse, RenNano, in conjunction with its high-throughput in vitro and in vivo antibody screening platforms, enabling large-scale development of fully human nanobody drugs.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=21909#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=21909\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=21909#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Biocytogen&#8217;s &#8216;Nano 100 Project&#8217; Aims to Develop Over 100 Fully Human Nanobody Drugs\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Biocytogen's 'Nano 100 Project' Aims to Develop Over 100 Fully Human Nanobody Drugs - Insight, China&#039;s Pharmaceutical Industry","description":"China-based Biocytogen Pharmaceuticals (Beijing) Co., Ltd has announced the launch of the \u201cNano 100 Project,\u201d an ambitious initiative designed to develop fully human nanobody drugs for over 100 targets. This project leverages Biocytogen\u2019s proprietary fully human nanobody mouse, RenNano, in conjunction with its high-throughput in vitro and in vivo antibody screening platforms, enabling large-scale development of fully human nanobody drugs.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=21909","og_locale":"en_US","og_type":"article","og_title":"Biocytogen's 'Nano 100 Project' Aims to Develop Over 100 Fully Human Nanobody Drugs","og_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","og_url":"https:\/\/flcube.com\/?p=21909","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2023-02-21T13:30:00+00:00","article_modified_time":"2025-01-18T13:34:08+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=21909#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=21909"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Biocytogen&#8217;s &#8216;Nano 100 Project&#8217; Aims to Develop Over 100 Fully Human Nanobody Drugs","datePublished":"2023-02-21T13:30:00+00:00","dateModified":"2025-01-18T13:34:08+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=21909"},"wordCount":280,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["Biocytogen Pharmaceuticals","Biotech","Multi-specific antibodies"],"articleSection":["Company","R&amp;D"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=21909#respond"]}],"copyrightYear":"2023","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=21909","url":"https:\/\/flcube.com\/?p=21909","name":"Biocytogen's 'Nano 100 Project' Aims to Develop Over 100 Fully Human Nanobody Drugs - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2023-02-21T13:30:00+00:00","dateModified":"2025-01-18T13:34:08+00:00","description":"China-based Biocytogen Pharmaceuticals (Beijing) Co., Ltd has announced the launch of the \u201cNano 100 Project,\u201d an ambitious initiative designed to develop fully human nanobody drugs for over 100 targets. This project leverages Biocytogen\u2019s proprietary fully human nanobody mouse, RenNano, in conjunction with its high-throughput in vitro and in vivo antibody screening platforms, enabling large-scale development of fully human nanobody drugs.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=21909#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=21909"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=21909#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Biocytogen&#8217;s &#8216;Nano 100 Project&#8217; Aims to Develop Over 100 Fully Human Nanobody Drugs"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/21909","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=21909"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/21909\/revisions"}],"predecessor-version":[{"id":21910,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/21909\/revisions\/21910"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=21909"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=21909"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=21909"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}